No spam - just the good stuff

Subscribe to our newsletter

News

Mitochondria

“Whole-body mitochondrial transfusion” start-up lands funding

Harvard spin-off Cellvie Inc closes $5M seed round

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics for the treatment of chronic and age-related diseases.

CohBar announces preclinical collaboration with NIAID

New Longevity supplement targets cognitive decline

Gut health shines a light on Longevity

Joined-up thinking and the hallmarks of aging

Calcium and ROS crosstalk: a key to extending healthspan?

GDF15 protects from age‐related metabolic phenotypes

New CRISPR-free gene-editing tool exploits bacterial warfare

Longevity investment: Apollo aims for the moon

Off-patent protein could be a key to Longevity

Metformin boost for inflammaging research

Two novel anti-aging targets identified

Pathway to Longevity: get rid of zombie cells

Targeting mitochondria to fight aging

Next generation of senescence research

Elysium announces epigenetic aging clinical trial

Dr Nir Barzilai: Creating a template for all aging trials

Taking life-extending drug Rapamycin to the next level

Metformin could limit the health benefits of exercise

Parkinson’s charity backs new biotech NRG Therapeutics

Heathspan boost as researchers find link between mitochondria and osteoporosis

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.